KPV + LL-37 Research Reference

Catalog classification, reference sizes, lab math links, and source-backed data. Educational use only — not medical advice.

Researched for: KPV LL-37 combination evidence

Structural Blend blend Blend verified

Also known as: KPV/LL37

Quick Facts

Reference Sizes
10 mg total
Components
KPV + LL-37
Calculator
Preset available
Storage
Use source-label storage wording. Track lot, storage location, and open/reconstitution date.
Solubility
Charge pH ionic strength and concentration may affect peptide interaction and stability

Blend Components

This entry is a multi-compound blend. Each component can be opened individually in the reconstitution calculator.

Component
KPV
Calculator Profile
Component
LL-37
Calculator Profile
Open All in Blend Calculator

Component amounts shown are arithmetic starters based on equal distribution. Edit values in the calculator before saving.

Catalog Description

KPV + LL-37 combines KPV + LL-37 into a single research protocol. Each component is independently studied; this entry summarizes the individual evidence base for the combination, since no unified safety/efficacy dataset covers the mixed formulation unless noted below. KPV: C-terminal tripeptide of alpha-MSH; suppresses inflammation via NF-kB inhibition with strong preclinical evidence in gut and skin conditions; transported across intestinal epithelium intact. LL-37: Human cathelicidin antimicrobial peptide (hCAP-18 C-terminal fragment); broad-spectrum antimicrobial activity plus cellular effects including chemotaxis, angiogenesis, and epithelial wound repair. This is a community-stacking combination assembled from two independently studied compounds rather than a pharmaceutical sponsor's dedicated fixed-dose combination program - no dedicated human combination trial exists for this exact pairing as of this writing.

Catalog descriptions reflect research context only. Not a medical claim or treatment recommendation.

Research Profile

Half-Life
Component-specific; no combination pharmacokinetic study exists
Onset
Not established for the fixed blend
Administration Routes (Research)
Laboratory useTopical or SC use is unvalidated

Reported Research Effects

Reported Research Side Effects

Data source: Individual-component preclinical literature and fixed-blend evidence gap

Reflects preclinical/research literature context only. Not a medical claim, dosing instruction, or treatment recommendation.

Research Protocols Reported in the Literature

Research Interactions

Flagged Avoid / Caution Combinations (Research)

Reflects patterns reported in research/community literature only. Not a safety guarantee, medical advice, or interaction warning for human use.

Research Notes

KPV is primarily studied as an anti-inflammatory tripeptide while LL-37 is a host-defense peptide with context-dependent inflammatory effects. No study establishes that co-formulation is beneficial or compatible.

Supplementary research context only. Not medical advice or a treatment recommendation.

Sources

KPV intestinal inflammation study — PubMed (NIH)
https://pubmed.ncbi.nlm.nih.gov/18061177/
LL-37 biology review — PubMed (NIH)
https://pubmed.ncbi.nlm.nih.gov/28088615/

Suggest a community source

Found a relevant Reddit or forum thread about this compound? Suggest it below. Every suggestion is reviewed by an editor before it appears -- nothing is published automatically.

Related Research Tools

Research Use Only. All content is for educational and research reference only. Not medical advice, a treatment recommendation, or guidance on human use. Compounds are not FDA-approved drugs unless specifically noted.

Scroll to Top